GENinCode

World DNA Day is an annual, global celebration of the discovery of the DNA double helix structure. This year is the 70th anniversary. It was on this day, in 1953, that Watson and Crick, with the precious contribution of Rosalind Franklin, described the structure of DNA and its double helix.

Thanks to this discovery, GENinCode tests now provide information about inherited conditions, disease diagnosis and improved risk assessment in cardiovascular disease.

Our tests are designed to help physicians make improved clinical decisions. With comprehensive genetic risk assessment, we are able to stratify patients at most risk and identify personalised treatment to prevent cardiovascular disease.

The GENinCode preventative cardiology approach is now being applied to healthcare systems across the US, UK and Europe to advance preventative care, deliver efficient resource management and improve outcomes.

The future is now! We are delighted with the American Journal of Preventive Cardiology publication representing the first major clinical publication showing the clinical utility of CARDIO InCode-Score to identify individuals at high genetic risk of coronary heart disease, the leading cause of death globally. Read more…

Revolutionary study offers hope in combating coronary heart disease Groundbreaking research by Kaiser Permanente paves the way for a personalised, predictive approach to combating coronary heart disease, potentially saving

GENinCode is delighted to announce their support for the NHS Understanding Genomics Event being held on Wednesday 8th November at 15 Hatfields, London. We look forward to attending the event and meeting with our friends and colleagues.

Please contact us at [email protected] if you would like to arrange a one-to-one meeting time or use the following link: https://www.convenzis.co.uk/genincode

In 2020, an estimated 523 million people had some form of cardiovascular disease (CVD), with approximately 19 million deaths attributable to CVD; this represents approximately 32% of all global deaths and is an absolute increase of 18.7% from 2010

Risk factors such as age, smoking, eating habits account for approx 50% of the likelihood of developing CVD with the remaining 50% risk related to an individuals inherited genetics.

By understanding our genetics we can help reduce the risk of CVD.

World Heart Day raises awareness of the worlds biggest killer and how we can prevent and treat cardiovascular disease.

Read more:

www.genincode.com

GENinCode announces its collaboration with the University Clinic Dresden, Germany for the implementation of LIPID inCode® to improve genetic diagnosis of hypercholesterolemia (high levels of cholesterol) and inherited familial hypercholesterolemia (FH) to prevent cardiovascular disease.

60% of the German population suffer from high levels of cholesterol and it is estimated that over a quarter of a million of these cases relate to FH. The University Clinic Dresden lipid centre constitutes one of the largest academic lipid apheresis centres globally. Approximately 6 million people in Germany live with heart and circulatory diseases, which accounts for 25% of all deaths annually.

LIPID inCode® detection of patients with inherited hypercholesterolemia supports improved treatment and prevention of cardiovascular disease.

🧬https://genincode.com/announcement-of-collaboration-with-university-clinic-dresden-germany-for-the-implementation-of-lipid-incode-testing/

The NHS expansion of LIPID inCode® testing for Familial Hypercholesterolemia (FH) enables the identification, earlier diagnosis and treatment of patients at high genetic risk of a heart attack, a vitally important step to help reduce cardiovascular disease mortality in the UK. Earlier detection of patients with FH supports better treatment and preventative care to avoid a heart attack.
The acceleration of LIPID inCode® testing will support the delivery of the NHS 10 Year Plan to identify at least 25% of those individuals suffering with FH by 2024 as part of the NHS genomics programme. The NHS 10 Year Plan for FH is at the forefront of cardiovascular clinical improvements to reduce CVD mortality in the UK.

NHS accelerates implementation of LIPID inCode® testing of patients suffering with hypercholesterolemia and familial hypercholesterolemia NHS earmarks budget to expand GENinCode’s LIPID inCode® polygenic testing to prevent Cardiovascular Disease Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease, announces the expansion of its collaboration with the Academic Health Scienc...

World DNA Day is an annual, global celebration of the discovery of the DNA double helix structure. This year is the 70th anniversary. It was on this day, in 1953, that Watson and Crick, with the precious contribution of Rosalind Franklin, described the structure of DNA and its double helix.

Thanks to this discovery, GENinCode tests now provide information about inherited conditions, disease diagnosis and improved risk assessment in cardiovascular disease.

Our tests are designed to help physicians make improved clinical decisions. With comprehensive genetic risk assessment we are able to stratify patients at most risk and identify personalised treatment to prevent cardiovascular disease.

The GENinCode preventative cardiology approach is now being applied to healthcare systems across the US, UK and Europe to advance preventative care, deliver efficient resource management and improve outcomes.

➡️ https://www.genincode.com/us-cpt-pla-code-granted-for-cardio-incode-score-cic-score-_-cpt-pla-code-is-key-component-for-reimbursement-from-private-medical-insurance-and-medicare/

We are delighted to announce the collaboration with the Extremadura Health Service region of Spain (SES) for the implementation of the CARDIO inCode-SCORE® (CIC-SCORE) genetic test to improve the prevention of cardiovascular diseases in Primary Care.

Learn more about this here: We are delighted to announce the collaboration with the Extremadura Health Service region of Spain (SES) for the implementation of the CARDIO inCode-SCORE® (CIC-SCORE) genetic test to improve the prevention of cardiovascular diseases in Primary Care.



Learn more about this here:

Extremadura Health Service implements the CARDIO inCode® genetic test to identify patients with a high genetic risk of cardiovascular disease in Primary Care. First pilot test in Spanish Primary Care, resulting from an agreement between the Predictive Genetics company GENinCode and the Extremadura Health Service, to improve cardiovascular disease (CVD) prevention. CARDIO inCode® is a world leading Personalised Medicine test, with significant scientific a...

Learn more about this here:

https://www.genincode.com/approval-of-california-state-license-and-clia-certification-opens-us-market-2/

Approval of California state license and CLIA certification opens US market Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”), announces California state licensing approval and CLIA certification of its Irvine laboratory in California, enabling the provision of its products for the risk ass...

We are delighted to announce the BMJ publication and positive results of the ALDO study. This study was conducted in women with a BRCA mutation who defer preventative surgery. The ROCA Test identified cancer earlier and showed a cost saving benefit to NHS.

Learn more about this here:

https://www.therocatest.co.uk/

is an initiative to raise awareness of the prevalence of blood clots and actions individuals can take to mitigate the risk of this condition.
 
Importantly, inherited genetics play a significant role in determining the likelihood of suffering from thrombosis.
 
Please help raise awareness by sharing this post.
 

We are ready!

Next week begins the 38th World Congress of the International Society of Hematology (ISH) hosted by Spanish Society of Hematology and Hemotherapy (SEHH) , which will take place simultaneously with the # # National Congress of the Spanish Society of Thrombosis and Haemostasis (SETH) and the LXIV National Congress of the Spanish Society of Hematology and Haemotherapy.

👉 Come and visit us at our booth nº73 and discover our test THROMBO inCode for hereditary thrombophilia.

📍 Palacio de Congresos de Barcelona

📆 6-8 October 2022, Barcelona, Spain.


We are looking forward to seeing you !

www.hemato2022.com/en/

*** 31% of global deaths associated with cardiovascular diseases (heart attack and stroke) and globally, 1 in 14 people are living with a heart or circulatory disease.***

World Heart Day on 29 September raises awareness about heart health and ways to help prevent and treat cardiovascular disease (CVD).

Classic risk factors such as age, smoking and eating habits contribute approx. 50% to the likelihood of developing CVD. The remaining 50% is driven by inherited genetics.

By better understanding our inherited genetic risk we can take preventative action through lifestyle change and/or therapy treatment to help reduce the risk of a heart attack or stroke.

On this consider your family genetics!

Congratulations Iberdrola Medical Services for achieving runner-up prize, awarded in recognition of the ‘Best Workplace Health Promotion Action on Cardiovascular (CV) Health’.

Iberdrola continue to improve the CV health of its employees through its pioneering Cardiovascular Disease Prevention Program strengthened by the addition of the CARDIO inCode® genetic test.

➡️Link in Bio

What is FH? Most people have heard of cholesterol, but some people can have high cholesterol through a faulty gene in their bodies which can be passed onto their childre...

➡️ https://www.genincode.com/nhs-implementation-of-lipid-incode-testing-of-patients-suffering-with-hypercholesterolemia-and-familial-hypercholesterolemia/

GENinCode are proud to have supported the Annual HEART U.K. 2022 conference this week, bringing together specialists and healthcare professionals from across the country. We continue to work tirelessly with all our friends, colleagues and patients in the fight against Hypercholesterolemia, Familial Hypercholesterolemia and Cardiovascular Disease to provide globally leading testing and diagnosis to enable preventative care and improved treatment.

GENinCode are proud to have supported the Annual HEART U.K. 2022 conference this week, bringing together specialists and healthcare professionals from across the country. We continue to work tirelessly with all our friends, colleagues and patients in the fight against Hypercholesterolemia, Familial Hypercholesterolemia and Cardiovascular Disease to provide globally leading testing and diagnosis to enable preventative care and improved treatment.

Cardiovascular disease (CVD) is a big problem across the whole of the UK. HEART UK partnered with Daiichi Sankyo to produce a report discussing ‘Closing the Cholesterol Gap’, which puts high cholesterol at the heart of the action on health inequalities. The report demonstrates the challenges and opportunities to improve cholesterol health across the UK.

https://www.heartuk.org.uk/news/latest/post/173-closing-the-cholesterol-gap

We are delighted to announce the collaboration with Indiana University (IU) School of Medicine, the largest medical school in the US who will be using CARDIO inCode - Score to study the genetic risk assessment of patients for the onset of atherosclerotic cardiovascular disease.

🧬 https://www.genincode.com/collaboration-with-indiana-university-school-of-medicine-study-for-testing-cardio-incode-score-for-the-risk-of-onset-of-cardiovascular-disease/

Collaboration with Indiana University School of Medicine – Study for testing Cardio inCode-SCORE for the risk of onset of cardiovascular disease Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with the Indiana University School of Medicine (“IU”). IU is the largest medical school in the US and will undertake a ‘Proof of Concept’ st...

We are pleased to be working in collaboration with GENinCode PLC to pilot the use of Lipid inCode® test for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia.

Read more ▶️ https://www.genincode.com/nhs-pilot-for-polygenic-testing-of-uk-patients-suffering-with-hypercholesterolemia-and-familial-hypercholesterolemia/

We are pleased to announce the collaboration with the Academic Health Science Network for the North East and North Cumbria ("AHSN NENC") to pilot the use of Lipid inCode® test for the diagnosis of hypercholesterolemia (high levels of cholesterol) and familial hypercholesterolemia ("FH")

Read more 👉🏻https://www.genincode.com/nhs-pilot-for-polygenic-testing-of-uk-patients-suffering-with-hypercholesterolemia-and-familial-hypercholesterolemia/

NHS pilot for polygenic testing of UK patients suffering with hypercholesterolemia and familial hypercholesterolemia Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces a collaboration with the Academic Health Science Network for the North East and North Cumbria (“AHSN NENC”) to pilot the use of its Lipid inCode® test for the di...

Cardiovascular (heart) disease is the leading cause of death globally, with most heart conditions having a strong underlying genetic or familial link, taking an estimated 17.9 million lives each year.

The European Heart Day (14th March) is an opportunity to inform people about cardiovascular disease (CVD).

Cardiovascular risk factors such as age, smoking and eating habits contribute 50% of the likelihood of developing CVD. The remaining 50% contribution is driven by inherited genetics.

By better understanding our inherited genetic risk we can take preventative action through lifestyle change or therapy intervention to reduce the risk of developing CVD.

On this don’t ignore your family genetics!

Read more here:

https://www.genincode.com/cardio-incode-genetic-test-prevent-heart-attack/

https://www.genincode.com/es/cardio-incode-test-genetico-prevencion-corazon/

We are delighted to announce the successful completion of our NHS clinical study and positive results for Lipid inCode® - A genetic test for hypercholesterolemia sufferers (high levels of cholesterol).

The results mark a breakthrough in helping the NHS rapidly identify and diagnose patients with genetic weakness to metabolise cholesterol thereby enabling more precise treatment to prevent the onset of cardiovascular disease.



Read More

Positive results for Lipid inCode® in NHS clinical study _ Lipid inCode® offers greater diagnostic information for hypercholesterolemia sufferers over current NHS standard Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the successful completion of its NHS clinical study and positive results for its Lipid inCode® test (“Lipid inCode®”) for hypercholesterolemia (high levels of c...

GENinCode the predictive genetics and cardiovascular disease company focused on the prevention of cardiovascular disease, announces the filing of its Pre-Submission for Cardio inCode-SCORE with the Food and Drug Administration (FDA). Cardio inCode-SCORE is an in-vitro diagnostic test which assesses an individual's combined genetic and clinical risk to predict and prevent cardiovascular disease ("CVD").

FDA Pre-Submission Filed for Cardio inCode-SCORE_Commencement of regulatory pathway for US market approval OXFORD, England, January 11, 2022 (Newswire.com) – GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces the filing of its Pre-Submission for Cardio inCode-SCORE with the Food and Drug Administration (FDA). Cardio inCode-SCORE is ...

Improving risk assessment and prevention will help avoid 1 in 4 people dying from conditions related to blood clots. VTE is also the #1 cause of preventable deaths in hospital.

is an initiative to raise awareness of the prevalence of blood clots and actions individuals can take to mitigate the risk of this condition. Importantly, inherited genetic predisposition accounts for approximately 60% likelihood of suffering from thrombosis.

This lets help to raise awareness by sharing this post.

Familial hypercholesterolemia is the most common genetic disease that manifests itself from birth and is transmitted from parent to child. Detection of familial hypercholesterolemia is essential to prevent myocardial infarction or cardiovascular death. Effective treatment is available! This lets help to raise awareness.

Why do some people with coronavirus have no symptoms and others get extremely ill? This is one of the pandemic's biggest puzzles.
A study in Nature of more than 2,200 intensive care patients has identified specific genes that may hold the answer.


http://ow.ly/6Ojb50DbIev

Covid: Genes hold clues to why some people get severely ill A study has identified genes that provide clues about why some people get seriously ill from Covid-19.

How does COVID-19 effect patients with Cardiovascular disease in comparison to Influenza?
Read more in the recent study 'Cardiovascular implications of COVID-19 versus influenza infection: a review' http://ow.ly/5Ev250DbHQ3

Cardiovascular implications of COVID-19 versus influenza infection: a review Due to the overlapping clinical features of coronavirus disease 2019 (COVID-19) and influenza, parallels are often drawn between the two diseases. Patients with pre-existing cardiovascular diseases (CVD) are at a higher risk for severe manifestations of both illnesses. Considering the high transmiss...